Tags

Type your tag names separated by a space and hit enter

CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
BMC Cancer 2019; 19(1):1140BC

Abstract

BACKGROUND

Recent studies have found that inflammatory response is involved in the pathogenesis of ovarian cancer. Advanced ovarian cancer is often presented with ascites that is rich in cytokines, inflammatory factors or cancer cells. Therefore, it is important to study the microenvironment of ascites in order to further clarify the occurrence and progression of ovarian cancer. As a pro-inflammatory factor, the Cyr61 expression patterns are inconsistent in human tumors. Although it has been reported that Cyr61 is related to the progression of ovarian cancer, its specific mechanism is not yet clear. This study sought to evaluate the Cyr61 levels of ascites, serum and different tissues of ovarian cancer to explore the potential association of Cyr61with the tumor-associated inflammatory microenvironment of EOC.

METHODS

Tumor specimens were procured from patients with ovarian serous cystadenocarcinoma and ovarian serous cystadenoma. Cyr61 and IL-6 levels of serum or ascites were determined by ELISA (Enzyme-Linked ImmunoSorbent Assay), while Cyr61 expressions of different ovarian tumor tissues were evaluated by IHC (Immunohistochemistry). Then the correlation of Cyr61 level in ascites with clinicopathologic features was analyzed. And other laboratory data were obtained from medical records.

RESULTS

Both in ascites and serum, significantly higher Cyr61 levels were found in ovarian serous cystadenocarcinoma. In malignant ascites, higher Cyr61 level of ovarian serous cystadenocarcinoma was more closely associated with FIGO stage, initial tumor size > 10 cm and the residual tumor size. And the increased IL-6 level was linearly related to Cyr61 level. Moreover, the serum levels of Cyr61, IL-6 and CRP in advanced stage of ovarian cancer were much higher than those in early stage. Lastly, the IHC data demonstrate that Cyr61 expression of ovarian serous adenocarcinoma was higher than that of ovarian serous cystadenoma, but it was lower than the paired metastatic lesions.

CONCLUSIONS

As a pro-inflammatory factor, increased ascites Cyr61 level is associated with FIGO stage, initial tumor size > 10 cm and the residual tumor size. Moreover, serum Cyr61 may be used as a potential marker for EOC inflammatory response. Finally, Cyr61 may be involved in the process of tumor metastasis and progression by producing IL-6 and CRP in the EOC inflammatory microenvironment.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, People's Republic of China.Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China.Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, People's Republic of China.Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, People's Republic of China.Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127, China. diwen@renji.com. Shanghai Key Laboratory of Gynecologic Oncology, Shanghai, 200127, People's Republic of China. diwen@renji.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31766991

Citation

Shi, Jun, et al. "CYR61, a Potential Biomarker of Tumor Inflammatory Response in Epithelial Ovarian Cancer Microenvironment of Tumor Progress." BMC Cancer, vol. 19, no. 1, 2019, p. 1140.
Shi J, Huo R, Li N, et al. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. BMC Cancer. 2019;19(1):1140.
Shi, J., Huo, R., Li, N., Li, H., Zhai, T., Li, H., ... Di, W. (2019). CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. BMC Cancer, 19(1), p. 1140. doi:10.1186/s12885-019-6321-x.
Shi J, et al. CYR61, a Potential Biomarker of Tumor Inflammatory Response in Epithelial Ovarian Cancer Microenvironment of Tumor Progress. BMC Cancer. 2019 Nov 25;19(1):1140. PubMed PMID: 31766991.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. AU - Shi,Jun, AU - Huo,Rongfen, AU - Li,Ningli, AU - Li,Haichuan, AU - Zhai,Tianhang, AU - Li,Huidan, AU - Shen,Baihua, AU - Ye,Jing, AU - Fu,Ruojin, AU - Di,Wen, Y1 - 2019/11/25/ PY - 2018/05/18/received PY - 2019/10/31/accepted PY - 2019/11/27/entrez PY - 2019/11/27/pubmed PY - 2019/11/27/medline KW - Cyr61 KW - Epithelial ovarian cancer KW - Tumor progression KW - Tumor-associated inflammatory microenvironment SP - 1140 EP - 1140 JF - BMC cancer JO - BMC Cancer VL - 19 IS - 1 N2 - BACKGROUND: Recent studies have found that inflammatory response is involved in the pathogenesis of ovarian cancer. Advanced ovarian cancer is often presented with ascites that is rich in cytokines, inflammatory factors or cancer cells. Therefore, it is important to study the microenvironment of ascites in order to further clarify the occurrence and progression of ovarian cancer. As a pro-inflammatory factor, the Cyr61 expression patterns are inconsistent in human tumors. Although it has been reported that Cyr61 is related to the progression of ovarian cancer, its specific mechanism is not yet clear. This study sought to evaluate the Cyr61 levels of ascites, serum and different tissues of ovarian cancer to explore the potential association of Cyr61with the tumor-associated inflammatory microenvironment of EOC. METHODS: Tumor specimens were procured from patients with ovarian serous cystadenocarcinoma and ovarian serous cystadenoma. Cyr61 and IL-6 levels of serum or ascites were determined by ELISA (Enzyme-Linked ImmunoSorbent Assay), while Cyr61 expressions of different ovarian tumor tissues were evaluated by IHC (Immunohistochemistry). Then the correlation of Cyr61 level in ascites with clinicopathologic features was analyzed. And other laboratory data were obtained from medical records. RESULTS: Both in ascites and serum, significantly higher Cyr61 levels were found in ovarian serous cystadenocarcinoma. In malignant ascites, higher Cyr61 level of ovarian serous cystadenocarcinoma was more closely associated with FIGO stage, initial tumor size > 10 cm and the residual tumor size. And the increased IL-6 level was linearly related to Cyr61 level. Moreover, the serum levels of Cyr61, IL-6 and CRP in advanced stage of ovarian cancer were much higher than those in early stage. Lastly, the IHC data demonstrate that Cyr61 expression of ovarian serous adenocarcinoma was higher than that of ovarian serous cystadenoma, but it was lower than the paired metastatic lesions. CONCLUSIONS: As a pro-inflammatory factor, increased ascites Cyr61 level is associated with FIGO stage, initial tumor size > 10 cm and the residual tumor size. Moreover, serum Cyr61 may be used as a potential marker for EOC inflammatory response. Finally, Cyr61 may be involved in the process of tumor metastasis and progression by producing IL-6 and CRP in the EOC inflammatory microenvironment. SN - 1471-2407 UR - https://www.unboundmedicine.com/medline/citation/31766991/CYR61,_a_potential_biomarker_of_tumor_inflammatory_response_in_epithelial_ovarian_cancer_microenvironment_of_tumor_progress L2 - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6321-x DB - PRIME DP - Unbound Medicine ER -